Published June 8, 2021 | Version 1
Dataset Open

Identification, Mapping and Relative Quantitation of SARS-CoV-2 Spike Glycopeptides by Mass-Retention Time Fingerprinting

Description

We describe an analytical method for the identification, mapping and relative quantitation of glycopeptides from SARS-CoV-2 Spike protein. The method may be executed using a LC-TOF mass spectrometer, requires no specialized knowledge of glycan analysis and exploits the differential resolving power of reverse phase HPLC. While this separation technique resolves peptides with high efficiency, glycans are resolved poorly, if at all. Consequently, glycopeptides consisting  of the same peptide bearing different glycan structures will all possess very similar retention times and co-elute.  Rather than a disadvantage, we show that shared retention time can be used to map multiple glycan species to the same peptide and location. In combination with MSMS and pseudo MS3, we have constructed a detailed mass-retention time database for Spike glycopeptides. This database allows any accurate mass LC-MS laboratory to reliably identify and quantify Spike glycopeptides from a single overnight elastase digest in less than 90 minutes.

 

 

 

Notes

This upload consists of raw LC-MS and LC-MSMS data to accompany this paper and the Mass Retention Time Database it refers to. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan, Diamond Light Source Limited. The CMD receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada througµgh Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z].

Files

200421_RBD6H_1ug.d.zip

Files (911.8 MB)

Name Size Download all
md5:dc962b7ee8f115cb568538cb6cd046aa
14.3 MB Preview Download
md5:e5cf5e18795d241a9e4c50aaea1d5f35
13.5 kB Preview Download
md5:c6c741c35e239fd555fde96a53316af0
14.0 kB Preview Download
md5:3dd70ab291e3660cc87baf76dca38bec
13.3 kB Preview Download
md5:d068c7a68d57972e682553fdbb2df5ee
13.7 kB Preview Download
md5:c7a7a74e68eae73405c346867b76b7aa
171.0 MB Preview Download
md5:8e0c86685c713b654e8d579ffcc32321
263.7 MB Preview Download
md5:97a4463302464d17fd6b4cc1e933359e
462.7 MB Preview Download